Your browser doesn't support javascript.
loading
A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds.
Gallant-Behm, Corrie L; Piper, Joseph; Dickinson, Brent A; Dalby, Christina M; Pestano, Linda A; Jackson, Aimee L.
Affiliation
  • Gallant-Behm CL; miRagen Therapeutics, Inc., Boulder, Colorado.
  • Piper J; miRagen Therapeutics, Inc., Boulder, Colorado.
  • Dickinson BA; miRagen Therapeutics, Inc., Boulder, Colorado.
  • Dalby CM; miRagen Therapeutics, Inc., Boulder, Colorado.
  • Pestano LA; miRagen Therapeutics, Inc., Boulder, Colorado.
  • Jackson AL; miRagen Therapeutics, Inc., Boulder, Colorado.
Wound Repair Regen ; 26(4): 311-323, 2018 07.
Article in En | MEDLINE | ID: mdl-30118158

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Wound Healing / Wounds and Injuries / Diabetic Foot / MicroRNAs / Angiogenesis Inducing Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: Wound Repair Regen Journal subject: DERMATOLOGIA Year: 2018 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Wound Healing / Wounds and Injuries / Diabetic Foot / MicroRNAs / Angiogenesis Inducing Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: Wound Repair Regen Journal subject: DERMATOLOGIA Year: 2018 Type: Article